EWA
KROS icon

EverSource Wealth Advisors’s Keros Therapeutics KROS Stock Holding History

EverSource Wealth Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1K Buy
1,039
+803
+340% +$8.95K ﹤0.01% 2846
2026
Q1 		$2.6K Buy
236
+33
+16% +$510 ﹤0.01% 3547
2025
Q4 		$4.13K Sell
203
-37
-15% -$649 ﹤0.01% 3197
2025
Q3 		$3.8K Buy
240
+190
+380% +$2.81K ﹤0.01% 3272
2025
Q2 		$668 Buy
50
+40
+400% +$540 ﹤0.01% 3826
2025
Q1 		$102 Buy
+10
New +$116 ﹤0.01% 3828

Other funds holding KROS

Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
NC
nVerses Capital Wellington, Florida $65M AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

EverSource Wealth Advisors's KROS Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Keros Therapeutics (KROS) stake by 340% in Q2 2026, buying an estimated $8.95K and bringing the position to 1,039 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2846.

EverSource Wealth Advisors first reported a position in KROS in Q1 2025 and has held it in 6 quarters since. 23 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • EverSource Wealth Advisors held 1,039 shares of Keros Therapeutics worth $11.1K as of Q2 2026.
  • EverSource Wealth Advisors bought 803 Keros Therapeutics shares in Q2 2026, an estimated $8.95K.
  • Keros Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2846 holding.
  • EverSource Wealth Advisors first reported a position in Keros Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 23 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.